Editas Medicine, Inc.
corporate_fare Company Profile
Editas Medicine, Inc. (NASDAQ:EDIT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for EDIT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for EDIT spans 10-Q, 8-K, 424B5, S-3MEF.
Recent high-impact activity:
- Editas 10-Q: $190.2M Cash, Runway Into 2H 2028, Q3 Loss Narrows to $23.4M
- Editas Q3 Loss Narrows to $23.4M; Cash Runway Extended Into 2H 2028
- Editas Q3 Loss Narrower Than Expected at $23.4M vs $27.7M Estimate
- Editas Medicine Cleared to Start First-in-Human Trial of EDIT-401 for Hyperlipidemia
- Editas Wins Approval to Start First-In-Human Trial of Gene-Editing Therapy EDIT-401
Financial Snapshot
Short Interest & Short Volume
17.60 days to coverFINRA reported short interest of 38,720,295 shares in EDIT as of the October 30, 2026 settlement, a 1.4% increase from the prior period — about 17.6 days to cover at its recent average daily volume. On November 20, 2026, 57.3% of EDIT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for EDIT, detected from its recent SEC filings · based on capital-structure filings through 2026-08-31.
Public Offering Priced · Significant Share Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →